Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Africa Health Minister Denounces MNC Campaign Against Generics Law

This article was originally published in PharmAsia News

Executive Summary

South Africa's health minister accused multinational drug makers of hatching a "genocide" plot against its population by limiting its access to generic life-saving treatments.

South Africa's health minister accused multinational drug makers of hatching a "genocide" plot against its population by limiting its access to generic life-saving treatments. Aaron Motsoaledi cited a $600,000 publicity campaign by MNCs to build opposition to the implementation of a new law allowing generics of patented drugs while increasing regulatory hurdles for registering patents and rolling them over. The law was enacted consistent with a government plan to encourage a local generics industry to compete with branded drugs dominated locally by Adcock Ingram and Aspen Pharmacare. (Click here for more)

"S. Africa Slams Big Pharma In Generic Drugs Row" - Reuters (1/17/2014)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC085772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel